This CME activity is derived from content presented at the 2026 AANEM Annual Meeting in Orlando, Florida. The expert faculty, Drs. Jeffrey Allen, Marinos Dalakas, and Katherine Ruzhansky will first review the pathophysiology of chronic inflammatory demyelinating polyneuropathy as well as the current standards of care and unmet needs for patients with CIDP. Following, the faculty will examine the current clinical trial data for new and emerging complement inhibitor therapeutics for the long-term management of patients with CIDP. The faculty will then discuss best practices for applying complement inhibitor therapeutics for their potential role when individualizing treatment plans to improve outcomes in patients with CIDP. To conclude, the faculty will present a patient case highlighting best practices for the treatment and management of patients with chronic inflammatory demyelinating polyneuropathy.
Neuromuscular disease specialists, neurologists, and other healthcare providers who manage patients with CIDP
Examine the pathophysiology of CIDP and the current standards of care and unmet needs for patients with CIDP
Evaluate the current clinical trial data for new and emerging complement inhibitor therapeutics for the long-term management of patients with CIDP
Discuss best practices for applying complement inhibitor therapeutics for their potential role when individualizing treatment plans to improve outcomes in patients with CIDP
Welcome & Introductions
CIDP Update: Pathophysiology, Accuracy of Diagnosis, Unmet Patient Needs
Clinical Trial Update
Managing Patients Who Do Not Respond to Standard of Care Therapies and Individualizing Treatment
Patient Case & Faculty Panel Discussion
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Jeffrey Allen, MD
|
Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Alnylam; Amgen Inc.; Annexon, Inc.; argenx; AstraZeneca; CSL Behring; Dianthus Therapeutics; Grifols; Immunovant; Johnson & Johnson; Sanofi; Takeda Pharmaceutical Company Limited |
| Marinos Dalakas, MD, PhD
|
Consultant/Advisor: Adicet Bio; Amgen Inc.; argenx; Grifols; Shoreline Biosciences, Inc. |
| Katherine Ruzhansky, MD
|
Consultant Advisor: Amgen; Kyverna Therapeutics, Inc; UCB
Grant/Research Support: COUR Pharmaceuticals; Immunovant, Inc.; Janssen Pharmaceuticals, Inc.; Paradromics |
Timothy Hayes, MD, PhD; Kim Cheramie, PhD, MSN, RN, NPDA-BC; Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Sanofi.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
